Ipamorelin

Mechanism

Selective GHS-R agonist that promotes GH release without expected prolactin/cortisol elevation.

Reported effects

What sources associate with this compound. Reported categories, not outcomes we have graded — each would need its own citation and rung.

• Deeper sleep
• Recovery support
• Training capacity

Figures

Every figure below is replotted by this site from values published in the cited paper's text or tables — the numbers are the study's, the drawing is ours, and the evidence rung on each image is the rung of its source.

Reconstitution

mass ÷ diluent = concentration; dose ÷ concentration = volume; volume × the syringe factor = units on the barrel (100 for U-100, 40 for U-40). Run your own numbers.

Half-life, storage & sport

Elimination half-life

approximately 2 hours (human, IV infusion) — study. Gobburu et al., Pharm Res 1999; PK-PD modelling in healthy male volunteers.

Storage

Lyophilised: Stable at room temperature ~3 weeks; store desiccated below -18C. Reconstituted: 4C for 2-7 days; below -18C for future use; 0.1% HSA/BSA for long term; avoid freeze-thaw. — source. ProSpec technical datasheet. Supplier handling recommendation for research-grade lyophilate, not a per-compound stability study.

In sport (WADA 2026)

Prohibited, at all times — named S2.2.4 (growth hormone secretagogues). the list

The half-life on file is 2 h, measured by intravenous infusion. At the fastest schedule this record states — every 8 h — each dose has fallen to 6.3% of its own peak by the time the next is given. Nothing accumulates, and there is no loading phase to run. The record gives 7 to 21 times a week; the fastest is drawn.

The rise is not modelled and the axis is not a blood level. No absorption rate constant and no volume of distribution are on file, so each dose appears at full height the instant it is given, and the axis is percent of this compound's own peak.

Reported adverse effects

• Water retention

  Reportedonset: First weeksreported reversible

• Headache

  Reportedonset: Post-injectionreported reversible

• Injection site reaction

  Reportedonset: Immediatereported reversible

Literature on file 3

• animal in vivo
  Ipamorelin, the first selective growth hormone secretagogue (European Journal of Endocrinology 1998, cited 70x) graded on: an animal model — read from the indexed abstract — “rats”
• human RCT
  Pharmacokinetic-Pharmacodynamic Modeling of Ipamorelin, a Growth Hormone Releasing Peptide, in Human Volunteers (Pharmaceutical Research 1999, cited 26x) graded on: names a randomised controlled trial — the indexed publication type — “Randomized Controlled”

Not graded

1 citation whose study design could not be read from the title. Left ungraded rather than guessed at.

• not graded
  NCT01280344: Phase II Double-Blind Placebo-Controlled Dose Finding Study to Evaluate Safety/Efficacy of Ipamorelin Compared to Placebo for Recovery of Gastrointestinal Function in Patients Following Small or Large Bowel Resection w/Primary Anastomosis graded on: NCT01280344 is completed and has posted no results - a registration, not a reported outcome — “NCT01280344”

What is circulated not evidence 4

Claims passed around in community guides and vendor copy, recorded because they circulate — not because they are true. Each is shown with the page it was read from and what this record actually holds. Checked 2026-08-24.

• unverified community data dose ubiquitous nothing on file either way

  A fat-loss protocol of 200-300 mcg subcutaneously, two to three times daily, fasted and before bed, is circulated as standard.

  The effective dose per injection is 200–300mcg administered subcutaneously.

  On the record The corpus holds 100-300 mcg daily (raw: "100-300 mcg daily"), verified: false, with benefits listed as sleep, recovery and training capacity — not fat loss. The multiple-daily fat-loss framing is community-built on top of a record that does not name fat loss at all.

  Source 1

• unverified community data timing common nothing on file either way

  It is circulated that injecting within 90 minutes of eating wastes the dose because insulin blocks the lipolytic effect; a minimum 3-hour fast is prescribed.

  administer on an empty stomach (minimum 3 hours post-meal)

  On the record Nothing on file. No study of feeding state and ipamorelin's effects is in the record.

  Source 1

• unverified community data stacking ubiquitous nothing on file either way

  Stacking with CJC-1295 is circulated as producing 30-50% greater fat-mass reduction than ipamorelin alone.

  shows 30–50% greater fat mass reduction compared to ipamorelin monotherapy

  On the record Nothing on file. The corpus holds no combination study of ipamorelin with CJC-1295 and no fat-mass outcome for either alone; the percentage carries no citation on the page. The record notes WADA prohibition (S2.2.4 growth hormone secretagogues).

  Source 1

• unverified community data benefit common nothing on file either way

  A results expectation — measurable fat loss after 3-4 weeks when paired with a deficit and training — circulates as a timeline.

  measurable fat loss typically appears after 3–4 weeks of consistent dosing paired with caloric deficit and resistance training

  On the record Nothing on file. No human fat-loss outcome for ipamorelin is in the record; the recorded human trials concern GH release, not body composition.

  Source 1

Identity

PubChem CID 9831659 computed 3D conformer

Skeletal formulathe canonical depiction

Drawn by PubChem from CID 9831659, the identifier on this record.

Molecular weight

711.868

Molecular formula

C38H49N9O5

CAS number

170851-70-4

PubChem CID

9831659

InChI key

NEHWBYHLYZGBNO-BVEPWEIPSA-N

Sequence

XHXFK

SMILES

CC(C)(C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@H](CC2=CC3=CC=CC=C3C=C2)C(=O)N[C@H](CC4=CC=CC=C4)C(=O)N[C@@H](CCCCN)C(=O)N)N

InChI

InChI=1S/C38H49N9O5/c1-38(2,41)37(52)47-32(21-28-22-42-23-43-28)36(51)46-31(20-25-15-16-26-12-6-7-13-27(26)18-25)35(50)45-30(19-24-10-4-3-5-11-24)34(49)44-29(33(40)48)14-8-9-17-39/h3-7,10-13,15-16,18,22-23,29-32H,8-9,14,17,19-21,39,41H2,1-2H3,(H2,40,48)(H,42,43)(H,44,49)(H,45,50)(H,46,51)(H,47,52)/t29-,30+,31+,32-/m0/s1

Classified as

Ghrelin Receptor Agonismmechanism

This is the mechanism behind the compounds usually filed as secretagogues, and it explains why appetite effects appear in the same records as growth hormone effects rather than as an unrelated aside.

Subcutaneousroute

This is the route the reconstitution arithmetic assumes. Mass divided by diluent volume gives concentration, dose divided by concentration gives volume, and volume in mL multiplied by 100 gives units on a U-100 barrel: 5 mg in 2 mL is 2.5 mg/mL, and 0.25 mg comes out at 0.1 mL, which is 10 units.

Intravenousroute

A large share of the pharmacokinetic numbers attached to peptide records, half-life in particular, come from intravenous studies and often from animals. Those numbers describe an intravenous curve and do not transfer unchanged to a depot under the skin.

Also called

• Ipamorelin

Listed prices 309

What 191 shops we track listed for Ipamorelin, read from their own public catalogues on 2026-09-14. We take no commission on these and they are not ranked by any payment — how vendors are scored.

Share this record